Sutro Biopharma’s (STRO) “Overweight” Rating Reaffirmed at Piper Sandler
Sutro Biopharma (NASDAQ:STRO – Get Free Report)‘s stock had its “overweight” rating reissued by equities research analysts at Piper Sandler in a note issued to investors on Friday, Benzinga reports. They currently have a $11.00 target price on the stock. Piper Sandler’s price target would indicate a potential upside of 198.10% from the company’s previous […]
More Stories
Castle Rock Wealth Management LLC Increases Position in AbbVie Inc. (NYSE:ABBV)
Castle Rock Wealth Management LLC increased its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 1.8% during...
West Coast Financial LLC Has $14.52 Million Position in PepsiCo, Inc. (NASDAQ:PEP)
West Coast Financial LLC increased its stake in shares of PepsiCo, Inc. (NASDAQ:PEP – Free Report) by 0.1% in the...
Short Interest in Deutsche Telekom AG (OTCMKTS:DTEGY) Grows By 93.4%
Deutsche Telekom AG (OTCMKTS:DTEGY – Get Free Report) saw a large increase in short interest in the month of September....
Converge Technology Solutions Corp. (OTCMKTS:CTSDF) Short Interest Down 84.1% in September
Converge Technology Solutions Corp. (OTCMKTS:CTSDF – Get Free Report) saw a large drop in short interest in the month of...
Deutsche Börse AG (OTCMKTS:DBOEY) Short Interest Up 100.0% in September
Deutsche Börse AG (OTCMKTS:DBOEY – Get Free Report) saw a large increase in short interest in September. As of September...
Invinity Energy Systems (LON:IES) Trading Down 4.9% – Time to Sell?
Invinity Energy Systems plc (LON:IES – Get Free Report)’s stock price dropped 4.9% on Wednesday . The stock traded as...